“Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study

This publication has 19 references indexed in Scilit:

• The use of omalizumab in asthma
  Primary Care Respiratory Journal, 2008
• Global strategy for asthma management and prevention: GINA executive summary
  European Respiratory Journal, 2007
• Severe serum sickness–like syndrome after omalizumab therapy for asthma
  Journal of Allergy and Clinical Immunology, 2007
• The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK
  Primary Care Respiratory Journal, 2007
• Are the Asthma Guideline Goals Achieved in Daily Practice? A Population-Based Study on Treatment Adequacy and the Control of Asthma
  International Archives of Allergy and Immunology, 2005
• Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
  Allergy, 2004
• The effect of treatment with omalizumab, an anti‐IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma
  Allergy, 2004
• Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs
  New England Journal of Medicine, 2000
• A Comparison of Observational Studies and Randomized, Controlled Trials
  New England Journal of Medicine, 2000
• Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials.
  Thorax, 1992